  In hepatitis<pathogen> C<pathogen> virus<pathogen> ( HCV<pathogen>) , infection viral and The present study was conducted to determine the effect of biochemical and risk factors on treatment outcome in CHC patients in relation to their viral and host genotype. The present study was a prospective Pe- IFN efficacy study consisting of Peg-IFN-a/R therapy for 24-48 weeks including 250 HCV<pathogen> infected patients. Biochemical parameters were determined by Beckman Coulter AU680 automated analyzer. HCV<pathogen> and Interleukin 28B ( Wild outnumbered the variant genotypes in Although the